Can engineered immune cells tame autoimmune disease?

NCT ID NCT06318533

Recruiting now Disease control Sponsor: YANRU WANG Source: ClinicalTrials.gov ↗

First seen Aug 11, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This early-phase trial is testing whether a single infusion of engineered immune cells, called CAR NK cells, can safely and effectively treat people with moderate to severe autoimmune diseases that have not improved with standard treatment. The study will enroll 15 adults and will first assess safety, then look at how well the cells control the disease and how long they last in the body. The approach involves a short course of chemotherapy before the cell infusion to help the cells engraft.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Chimeric antigen receptor (CAR) NK cells, given after a short course of chemotherapy (fludarabine and cyclophosphamide)
What this could lead to: If successful, this could lead to a new treatment option for people with autoimmune diseases that haven't responded to standard therapies, potentially resetting the immune system.
What could go wrong: This is a very early, small trial (15 people) focused mainly on safety. The treatment may not work, and there are risks of side effects from the chemotherapy and the cell infusion, including immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE DISEASES

Contacts and locations

Locations

Affiliated Hospital of Jiangsu University
RECRUITING

Zhenjiang, Jiangsu, 212001, China
Jiangsu University Affiliated Hospital
RECRUITING

Zhenjiang, Jiangsu, 212001, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.